Sie suchten nach: confounding (Englisch - Maltesisch)

confounding factor
fattur ta' konfużjoni

without evident alternative aetiology or confounding factors
mingħajr etjoloġija alternattiva evidenti jew fatturi konfużjonali

(5) proper consideration of bias and confounding factors; and
5) konsiderazzjoni xierqa ta' preġudizzji u ta' fatturi li jistgħu jfixklu, u

os analysis was not adjusted for the potentially confounding effects of crossover.
analiżi os ma ġietx aġġustata għall-effetti potenzjalment li jfixlu lil dak li jkun tal-crossover.

confounding factors have included pre-existing liver disease or concomitant hepatotoxic medications.
fatturi li jaggravaw inkludew mard tal-fwied eżistenti minn qabel jew l-użu fl-istess waqt ta’ medikazzjonijiet epatotossiċi.

the mah should check regarding the possible confounding layouts with other pandemic vaccine supplied in eu.
l-mah għandu jiċċekkja rigward il-possibbiltà ta’ arranġamenti b’kunflitt ma’ vaċċini pandemiċi oħra fornuti fl-eu.

however, the majority of these hypotensive events were reported in patients who had confounding severe infections.
imma, l-biċċa l-kbira ta’ dawn il-każi ipotensivi kienu rrapportati f’pazjenti li kellhom infezzjonijiet severi, li huma impossibbli tisseparahom.

many patients had confounding medical conditions, some of which required therapy with agents that have been associated with the development of diabetes or hyperglycaemia.
Ħafna pazjenti kellhom kondizzjonijiet mediċi mħawwdin, li xi ftit minnhom kienu jeħtieġu terapija b’mediċini li kienu assoċjati ma’ l-iżvilupp tad-dijabete mellitus jew ta’ l-ipergliċemija.

many of the patients had confounding medical conditions, some of which required therapy with agents that have been associated with the development of diabetes mellitus or hyperglycaemia.
Ħafna mill-pazjenti kellhom kundizzjonijiet ta’ mard mhux daqshekk ċari, fejn xi wħud kellhom bżonn terapija b’mediċini li kienu magħrufa li jistgħu jikkawżaw id-dijabete jew l-ipergliċemija.

this is probably due to the confounding of adverse events by the uncontrolled disease process early on in the treatment course and the myriad concomitant medicinal products required to control symptoms and morbidity.
dan probabbilment hu frott tal-fatt li hu diffiċli tissepara l–episodji avversi wieħed mill-ieħor bil-proċess mhux ikkontrollat tal-marda kmieni matul il-kors tat-trattament u l-ħafna prodotti mediċinali konkomitanti li huma meħtieġa biex jiġu kkontrollati is-sintomi u l-morbidità.

all studies used statistical methods to control for confounding factors, including preferential prescribing of varenicline to healthier patients, although there is the possibility of residual confounding.
l-istudji kollha użaw metodi ta’ statistika biex jikkontrollaw il-fatturi ta’ tfixkil, inkluż preskrizzjoni preferenzjali ta’ varenicline lill-pazjenti aktar b’saħħithom, għalkemm hemm il-possibbiltà ta’ tfixkil residwu.

a pre-specified propensity score stratified analysis was used to adjust for measured baseline differences but residual confounding may, in spite of this, influence the results.
intużat analiżi stratifikata tal-punteġġ ta’ propensità speċifikata minn qabel biex jiġu aġġustati differenzi mkejla fil-linja bażi, iżda minkejja dan tfixkil residwu jista’ jinfluwenza ir- riżultati.

lower response rates were observed in patients over 100 kg bw; however, confounding factors in a small sample size make it unclear if in patients over 100 kg bw the dose was optimal to achieve an effect.
rati aktar baxxi ta’ rispons kienu osservati f’pazjenti li kellhom piż tal-ġisem ogħla minn 100kg, madankollu, f’kampjun żgħir fatturi li jistgħu jfixklu jagħmluha inqas ċara jekk fuq pazjenti li għandhom piż tal-ġisem ogħla minn 100kg id-doża kienetx l-aqwa waħda biex jintlaħaq effett.

patients with advanced stages of all or aml may have confounding medical conditions that make causality of adverse events difficult to assess due to the variety of symptoms related to the underlying disease, its progression and the co-administration of numerous medicinal products.
pazjenti li kienu jinsabu fi stati avvanzati ta ’ all jew aml għandhom mnejn ikollhom kondizzjonijiet mediċi li huma impossibbli tisseparahom li jagħmlu l- każwalità ta ’ każi avversi diffiċli biex tassessjahom minħabba varjetà ta ’ sintomi li għandhom x’ jaqsmu ma ’ l- marda fondamentali, l - progress tagħha u l- għotja flimkien ta 'prodotti mediċinali numerużi.

patients with advanced stages of malignancies may have numerous confounding medical conditions that make causality of adverse reactions difficult to assess due to the variety of symptoms related to the underlying disease, its progression, and the co-administration of numerous medicinal products.
pazjenti li jkollhom stadji avvanzati ta’ kanċer malinn jista’ jkollhom għadd ta’ kundizzjonijiet mediċi li jagħmlu l-identifikazzjoni tal-kawża ta’ l-effetti avversi diffiċli biex tkun stmata minħabba l-varjetà ta’ sintomi relatati mal-marda, l-avvanz tagħha, u l-għotja fl-istess ħin ta’ numru kbir ta’ prodotti mediċinali.

although in the majority of cases the information was too limited to allow a causality assessment, confounding factors such as pre-existing lupus, including potential incipient sle, were present in many of the remaining cases and the pathogenesis of sle/drug-induced lupus is still poorly understood and probably multifactorial, it does not appear unreasonable that xolair, a drug that forms immune complexes with ige with the potential to induce immune complex injury and for which events such as serum sickness have been rarely reported, could play a role in the pathogenesis of sle/drug-induced lupus.
minkejja li fil-biċċa l-kbira tal-każijiet it-tagħrif kien wisq limitat sabiex tkun tista’ sseħħ evalwazzjoni tal- każwalità, fatturi li ħolqu konfużjoni fosthom lupus eżistenti minn qabel, inkluż bidu potenzjali ta’ sle kienu preżenti f’bosta mill-każijiet li kien għad fadal u patoġenesi ta’ sle/lupus minħabba mediċini mhux magħrufa u x’aktarx multifattorjali, ma jidhirx irraġonevoli li xolair, mediċina li tifforma kumplessi immuni b’ige bil-potenzjal li tinduċi ħsara fil-kumpless immuni u li minħabba f’hekk episodji rari fosthom ta’ mard minħabba s-serum ġew irrappurtati, xorta jaf ikollu sehem fil- patoġenesi ta’ sle/lupus minħabba mediċini.